Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2706 - Patient-private disease evolution and heterogeneity in bilateral breast cancer

Date

10 Oct 2016

Session

Poster display

Presenters

Elena Fountzila

Citation

Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364

Authors

E. Fountzila1, V. Kotoula1, F. Zagouri1, E. Giannoulatou2, G. Kouvatseas3, G. Pentheroudakis1, T. Koletsa1, M. Bobos1, K. Papadopoulou1, E. Samantas1, E. Demiri1, S. Miliaras1, C. Christodoulou1, S. Chrisafi1, E. Razis1, F. Fostira1, D. Pectasides1, G. Zografos1, G. Fountzilas1

Author affiliations

  • 1 Data Office, Hellenic Cooperative Oncology Group (HeCOG), 11524 - Athens/GR
  • 2 Bioinformatics, Victor Chang Cardiac Research Institute, Darlinghurst/AU
  • 3 Biostatistics, Health Data Specialists Ltd, Athens/GR
More

Resources

Abstract 2706

Background

It is still unclear whether bilateral breast cancer (BBC) should be regarded as relapsed, metastatic or second primary tumors. Using targeted next generation sequencing (NGS), we explored paired BBC genotypes to identify potential genomic similarities and clonal origin of these tumors.

Methods

We examined 76 patients (75 women and one man) with BBC, 52 concurrent and 24 metachronous. Paraffin tumors (n = 155) with informative targeted NGS data were histologically reviewed and subtyped with immunohistochemistry (IHC). In a patient subset, peripheral blood genotypes were obtained with the same panel and/or upon testing for cancer predisposing genes (germline testing). We analyzed coding mutations (amino acid changing, minor allele frequency

Results

Breast histology and tumor IHC subtype were concordant in 85% and 61% of bilateral cases, respectively. We identified 258 mutations in 80 tumors (54 patients). TP53 and PIK3CA were the most frequently mutated genes (19% and 14%, respectively), followed by CDH1, GATA3 and MLL3. TP53 mutation rate was significantly higher in metachronous tumors (p 

Conclusions

Clonal origin is revealed in few patients for the examined genes. The present findings support that BBC tumors are mostly independent tumors arising in the same patient, which justifies current clinical practice.

Clinical trial identification

N/A

Legal entity responsible for the study

Hellenic Cooperative Oncology Group

Funding

Hellenic Cooperative Oncology Group internal research grant

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings